


Rivenprost

Chemical Properties

CAS No. :	256382-08-8
Formula:	C ₂₄ H ₃₄ O ₆ S
Molecular Weight:	450.59
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Prostaglandin E2 activates four distinct G protein-coupled receptors, EP1-4. Rivenprost is a potent and selective agonist for the EP4 receptor (K _i = 0.7, 56, 620, and >10,000 nM for EP4, EP3, EP2, and EP1, respectively). It has been used to promote EP4-mediated bone formation, prevent bone loss related to osteoporosis, drive osteoblast differentiation, and stabilize bone implants.[1][2][3][4][5] Rivenprost has also been used to support wound healing.[6]
Targets(IC50)	Others,Prostaglandin Receptor

Solubility Information

Solubility	DMF: 30 mg/mL (66.58 mM),Sonication is recommended. Ethanol: 30 mg/mL (66.58 mM),Sonication is recommended. DMSO: 20 mg/mL (44.39 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2193 mL	11.0966 mL	22.1931 mL
5 mM	0.4439 mL	2.2193 mL	4.4386 mL
10 mM	0.2219 mL	1.1097 mL	2.2193 mL
50 mM	0.0444 mL	0.2219 mL	0.4439 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Yoshida, K., Oida, H., Kobayashi, T., et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. *Proceedings of the National Academy of Sciences of the United States of America* 99(7), 4580-4585 (2002).
- Ninomiya, T., Hosoya, A., Hiraga, T., et al. Prostaglandin E2 receptor EP4-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. *European Journal of Pharmacology* 650, 396-402 (2011).
- Ito, M., Nakayama, K., Konaka, A., et al. Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. *Bone* 39, 453-459 (2006).
- Nakagawa, K., Imai, Y., Ohta, Y., et al. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. *Bone* 41, 543-548 (2007).
- Hayashi, K., Fotovati, A., Abu Ali, S., et al. Effect of a prostaglandin EP4 receptor agonist on early fixation of hydroxyapatite/titanium composite- and titanium-coated rough-surfaced implants in ovariectomized rats. *J. Biomed.Mater.Res.A* 92(3), 1202-1209 (2010).
- Honma, Y., Arai, I., Hashimoto, Y., et al. Prostaglandin D2 and prostaglandin E2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice. *European Journal of Pharmacology* 518, 56-62 (2005).

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481